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CONSEQUENCES OF SARCOPENIA AMONG NURSING HOME RESIDENTS 
AT LONG-TERM FOLLOW-UP  
Abstract 
The consequences of and transition into sarcopenia with long-term survival was 
investigated in the nursing home setting. Eligible residents from 11 nursing homes were 
followed-up 18-months after their assessment for sarcopenia using the European Working 
Group on Sarcopenia in Older People criteria, with other demographic, physical and 
cognitive health measures collected. Of the 102 older adults who consented at baseline, 22 
had died and 58 agreed to participate at follow-up, 51.7% of whom had sarcopenic. 
Sarcopenia at baseline was associated with a depression (p < .001), but not mortality, 
hospitalization, falls or cognitive decline at follow-up. Age was the strongest predictor of 
mortality (p = .05) with the relative risk of death increasing 5.2% each year. The prevalence 
of sarcopenia is high and increases with long-term survival in end-of-life care. However, 
the risk of sarcopenia-related mortality is not as great as from increasing age alone.  
Key words: Consequences, Mortality, Nursing-home, Sarcopenia
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Introduction 
According to the European Working Group on Sarcopenia in Older People 
(EWGSOP), sarcopenia is an age related syndrome defined by a progressive and 
generalized loss of muscle mass and muscle function (either or both of below normal 
muscle strength or physical performance).1 As a geriatric syndrome, sarcopenia affects 
quality of life, is associated with poor survival rates,2 plays an important role in the etiology 
of frailty and is highly predictive of several adverse health events in later life.3 In addition, 
it has been reported that in comparison to non-sarcopenic adults, those with sarcopenia are 
at greater risk of falls, are more likely to be physically disabled and have greater care 
needs.4, 5 
Following the definition review in 2010,1 a large a body of work has emerged looking 
to establish prevalence and risk factors of sarcopenia across varied older cohorts. However, 
due to variations in cohort characteristics, diagnostic and measure criteria, prevalence data 
are mixed.6 Conclusive is that sarcopenia increases rapidly after the age of 65 years, with 
prevalence being as high as 50% in people older than 80 years.7, 8 In addition, current 
research has identified male gender, low body mass index (BMI) and reduced physical 
activity as common risk factors to being sarcopenic.9, 10 
Work by our group has shown that in the environment where prevalence is highest, the 
nursing home,>40% of adults are sarcopenic.(Removed for blinding) However, while prevalence 
and risk factor data grows, longitudinal analysis of the consequence of and the progression 
to sarcopenia is scarce. Given the economical and personal implications of being 
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sarcopenic, a broader understanding of the consequences may assist in informing 
interventions pathways, particularly in light of evidence that a number of sarcopenia risk 
factors are modifiable.12, 13 The aim of this study was to report the implications of 
sarcopenia in nursing home residents at an 18 month follow-up, and to track progression 
in sarcopenia among those with no previous diagnosis.  
Methods 
Study design  
The study employed a longitudinal follow-up of randomly selected adults with 
secondary data collected 18 months after the parent-study baseline assessment. A detailed 
account of the methodologies used in the baseline cross-sectional study and of the reported 
sarcopenia prevalence and risk factors can be found elsewhere, including a CONSORT 
diagram detailing recruitment, randomization and assessment.(Removed for blinding) In brief, 273 
adults residing in 11 purposefully selected South East Queensland (Australia) nursing 
homes were randomized into the study from an eligible sample of 381 and total resident 
cohort of 709. The inclusion criteria were (i) ≥60 years, (ii) residing in a nursing home and 
(ii) could provide consent, self or by proxy given directly by the participants substitute 
decision maker or verbally to the facility Service Manager. Residents were excluded if 
they; (i) had a pacemaker; (ii) were end-stage palliative or terminal (iii) had difficult 
behaviors that would limit data collection; or (iv) had a medical condition or other issue 
that would limit data collection (eg. total uncommunicable deafness). Ninety-one 
individual self-consented and 11 consented by proxy to participate in the baseline study 
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(84.5 ± 8.2 years; > 70% women, 1204.2 ± 1220.1days in care). Consent to the baseline 
study included agreement to be approached at the 18-month follow-up and a secondary 
data set collected. Specifically, facilities were re-contacted and the follow-up study 
explained to the Service Manager, who was then given the list of participant per facility 
and a request to seek consent for participation. Consent for the follow-up study was 
considered appropriate given the time frame, setting and the risk of negative health change 
among participants. As with the baseline study, consent was obtained directly from 
cognitive sound participants or from the substitute decision maker of participant not able 
to consent themselves. The eligibility criteria were retained from the baseline study for the 
follow-up study. 
Approval for the study was provided by the Human Ethics Committee of the (Removed for 
blinding) University, and the nursing care provider’s internal ethics committee. 
Data Collection  
Participants were assessed individually and data collection was finalized at one facility 
before moving to the next. For low care participants, the research assistant (RA) was left 
to conduct the data collection without assistance. For high care and dementia participants, 
a facility staff member was present.  
Measures  
All measures were validated for use among old and very old adults and have been 
described in detail previously.10, 11 Where an individual could not complete a measure due 
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to health or disability issues the measure was excluded, with the exceptions of the 2.4 meter 
walk (scored at 0 if unable) to ensure a measure of physical performance. For individuals 
who were unable to or would not assent to the bioelectrical impedance analysis (BIA), 
baseline data were carried forward. 
Primary outcome: Sarcopenic  
Sarcopenia was measured using the EWGSOP definition, cut-off points and 
assessment criteria. Specifically, a diagnosis of sarcopenia required the presence of both 
low muscle mass and low muscle function (muscle strength or physical performance).1 
Muscle mass was measured using BIA (Maltron BF-906, Maltron International Ltd, 
Rayleigh, UK) with the participant lying flat and the standardized electrode placement. 
Skeletal Muscle Mass (SMM) was calculated from the equation (SMM = [(height2(cm) 
/resistance (ohms) x 0.401) + (gender x 3.825) + (age (yrs) x -0.071)] + 5.102), then divided 
by height2 (m) to give the Skeletal Muscle Index (SMI). The SMI cut-off of <8.87 kg/m2 
in men and <6.42kg/m2 in women were used to define low muscle mass. Muscle strength 
was measured by Jamar hand grip dynamometer (Sammons Preston Roylan, Bolingbrook, 
IL), using the individuals dominant hand with their elbow at 900 and locked at their side. 
The best of three trials was used in the analysis and cut-off points of < 30 and < 20 kg for 
men and women, respectively, used to define low muscle strength. Physical performance 
was measured by the Short Physical Performance Battery(SPPB) 2.4-meter walk. The best 
of three trials was retained for the analysis and the cut-off point of < 0.8 m/s used to define 
low physical performance. In addition, the remaining SPPB measures, the standing balance 
6 
 
and the repeated chair stands, where collected to allow the generation of the SPPB 
summary score.  
Secondary outcomes 
The RA collected height (cm) and weight (kg) by standardized methodologies. 
Demographics and clinical data were collected from facility records with outstanding 
variables collected directly from the participants. The Mini-Mental State Examination and 
the Geriatric Depression Scale were used to measure cognitive status and depression, 
respectively, and the Mini-Nutritional Assessment Instrument (MNA) to assess nutritional 
status.10 
Statistical analysis   
Within cohort, sex and group comparisons were made on demographic, functional and 
clinical variables between baseline and the follow-up by t-test (continuous data) and by 
Pearson’s chi-square test (categorical data). Between group (Sarcopenia versus No 
Sarcopenia at baseline) differences were investigated by repeated measures analysis of 
variance (2 x 2 ANOVA). Generalized linear models were used to quantify the effects of 
sarcopenia (diagnosed at baseline) on functional and clinical variables whist controlling 
for the sarcopenic risk factors of age, gender, BMI, physical activity level and nutritional 
status.10 For binary data including occurrence of death, hospitalization or a fall, prevalence 
was not rare and therefore modified Poisson regression models with robust estimation of 
SE values were used to calculate relative risk (RR).14 Data were analyzed through a 
combination of SPSS version 22.0 (SPSS Inc., Chicago, IL, USA) and the geepack 
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statistical package for the R programming language, version 3.1.3. Statistical significance 
were based on two-tailed tests with p<0.05 considered significant.  
Results  
Participants 
Twenty-two of the 102 baseline participants died within the 18-month follow-up 
period, and 58 of the surviving 80 participants consented to the follow-up analysis (85.7 ± 
8.2 years; > 70% women, 1970.8 ± 1403.7 days in care, 14 by substitute decision maker 
consent). Those who died had been in care for 1314.7 ± 884.1 days, were 88.3 ± 8.3 years 
of age at death, 13 were female and 9 had a baseline diagnosis of sarcopenia. Among those 
who did not consent to participate, 9 were unavailable, 7 refused, 4 had been relocated and 
2 were not consented by their substitute decision maker (Baseline: 82.8 ± 7.7 years, 983.2 
± 944.5 days in care, 40.9% sarcopenic (N; 9 of 22) versus 37.9% of those who did consent 
(N; 22 of 58)). Analysis of baseline measures revealed no difference between those who 
consented to the follow-up investigation and those who didn’t (p > .05). At the follow-up 
assessment, women were older, had a higher percent body fat and walked faster than men, 
while men were taller, heavier and had a higher SMI and lean mass than women (p < .05). 
Sixteen participants were unable (pacemaker or could not transferred to laying) or would 
not assent (behaviors) to the BIA measured. An overview of demographic, physical and 
mental health data at follow-up is given in table 1. 
Sarcopenia 
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At baseline 40.2% were classified sarcopenic, with prevalence higher in males 
(45.2%), but not statistically different to females (36.7%) (χ2 = .660, df = 1, p = 
.416).(Removed for blinding) At follow-up, sarcopenia prevalence increased to 51.7% (N = 30). 
Prevalence remained higher among males (70.6% versus 43.9%, males (N; 12 of 17) versus 
females (N; 18 of 41), respectively), and approached significance (χ2 = 3.427, df = 1, p = 
.064). Among those who died, there was no difference from baseline to time of death 
between sarcopenic (n = 9) and non-sarcopenic individuals (342.8 ± 143.0 versus 350.4 ± 
150.0 days, respectively; p =.906).  
Impact of sarcopenia on health outcomes 
Generalized linear models results demonstrate that depression was associated at 
baseline with sarcopenic status (p = .003), with a significant interaction effect (p = .002) 
identified between sarcopenic status and gender, highlighting that depression was highest 
in males with sarcopenia. In contrast, sarcopenic status was not associated with change in 
cognitive status or in SPPB (p ≥ .690) (Table 2). The Poisson regression approach revealed 
no significant association between a baseline diagnosis of sarcopenia and mortality, 
hospitalization or falls at follow-up in either the unadjusted or adjusted models (Table 3). 
Age was found to be the single best predictor of mortality (p = .05) with the relative risk 
of death increasing by 5.2% each year. 
Sarcopenia versus non-sarcopenic group change to follow-up 
Independent of sarcopenic status, a within group analysis revealed a significant 
decrease in walking speed, standing balance, SPPB summary score, grip strength and the 
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MNA (p ≤ .047) over 18 months till follow-up. For the group diagnosed non-sarcopenic at 
baseline, significant decreases in the SMI was found (p = .014) at follow-up. Between 
group analysis revealed a group*time effect for SMI (p = .041) and a between group 
difference for BMI, SMI, lean mass and grip strength (p ≤ .032) at follow-up. Data are 
presented in table 4.  
Discussion  
This study supports that the prevalence of sarcopenia in the nursing home setting is 
high15 and demonstrated an increase in prevalence with long-term survival. However, for 
long-term surviving residents an increase in age has a stronger association to mortality than 
a diagnosis of sarcopenia. This study also demonstrates that among long-term survivors, 
being non-sarcopenic was associated to greater negative change across measures of body 
composition, but not muscle function, than among those with a diagnosis of sarcopenia. 
While it would be assumed that increasing age in the nursing home setting would be a 
predictor of death and that sarcopenia prevalence continues to increase if untreated, to date 
few studies have explored this assumption.  
Sarcopenia is known to bring with it a number of negative consequences that increase 
with age and place the individual at an elevated risk of disability, institutionalization and 
declining health.1 According to Fried et al.16 sarcopenia has an important etiological role 
in the frailty process and harmful consequences, such as falls, functional decline, loss of 
independence, emergency room visit, hospital and nursing home admission, and mortality. 
Supporting the association to mortality, and using the same methodological technique 
10 
 
employed in this study, Landi et al.17 reported that at a 6-monthfollow-up older 
institutionalized Italians with sarcopenia had greater risk of mortality. Arango- Lopera et 
al.18 corroborated this associating at a three-year follow-up, but among community-
dwelling Turkish adults with muscle mass defined by calf circumference. 
In our study, 21.6% of the original cohort had died at follow-up, with time to death 
from diagnosis or risk of mortality demonstrating no difference between groups 
(sarcopenic and non-sarcopenic). In contrast, our study showed the risk of mortality had a 
stronger association to increasing age than to sarcopenia. This is in agreement with other 
research that reports sarcopenia a poor predictor and age as a stronger predictor of mortality 
in older subjects.19 In the present study, while still having a greater absolute value at follow-
up, those diagnosed non-sarcopenic at baseline experienced accelerated declines in SMI. 
This maybe reflective of a greater potential to decline within the non-sarcopenic group and 
that the sarcopenic group had reached a SMI plateau associated to survival. As an alternate 
predictors of mortality risk, Cheung et al.20 recently suggested that muscle mass and gait 
speed may be stronger individual indicators, which is supported by Srikanthan et al.21 who 
showed low muscle mass a better predictor of mortality than BMI. The presented study 
was focused on investigating the consequences of sarcopenia on long-term survival, but 
given these aforementioned associations, more work may be warranted looking at the 
independent components of a sarcopenic as alternate predictors of mortality in the nursing 
home setting.  
It is not surprising this study found no strong association between sarcopenia, falls risk, 
hospitalization and functional capacity. Specifically, in the nursing homes environment 
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risk of adverse events are already high, and associated to other factors such as increasing 
age, disease, extended sitting times, assisted transfers and the use of mobility aids.22 As 
with mortality, sarcopenia may influence these markers of dependence, but be only one 
factor in geriatric decline that drives increased risk. In contrast, the interplay between 
depression and sarcopenia found here supports the association identified previously,23 a 
relationship thought to be influenced by declining physical independence and poor health 
outcomes.1, 24 
Moreover, it is not surprising individuals continue to decline across markers of health 
and wellbeing in the nursing home setting, prominently associated to extended sitting, high 
levels and the progression of chronic disease, and a lack of intervention to promote physical 
gains.25, 26 However, in a recent review of exercise in the nursing home setting, evidence 
supports that appropriate physical activity, and specifically weight bearing exercise, can be 
effective at increasing muscle mass, muscle strength and physical performance, thereby 
targeting the three physical components associated to sarcopenia.27 This is supported by 
recent work from our group that showed a reduced transition in sarcopenia among adults 
doing resistance training, accompanied by increased muscle strength and physical 
performance following 24 weeks of twice weekly progressive resistance plus balance 
training.28  
Current research in the field of sarcopenia has seen a significant body work of appear 
in an abbreviated period. In the presence of this work, the current study is a reminder for 
clinicians that while negative consequences can follow a diagnosis of sarcopenia, in end of 
life care it is increasing ages that presents the greatest risk for mortality. For researchers 
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and care providers working in the nursing care sector and concerned about the impact of 
long-term survival for residents, this study and others done by our group is suggestive that 
when left untreated sarcopenia can continue to have negative consequences for resident 
health and that with an intervention of exercise, significant positive physical changes can 
occur.25, 28.   
This study has several limitations. The small sample size and that some data were 
carried forward may have decreases the statistical power of the study.29 Even though our 
exclusion criteria aimed to maximize the intake at baseline, low voluntary participation 
rates (common in this setting) and an 18 month follow-up period in end-of-life care has 
significant implication for sample numbers. Still our baseline cohort sample and death rate 
was not dissimilar to that reported in short-term consequence investigations previously.17 
In addition, due to the exclusion of residents with difficult behaviors or at end-of-life, data 
must be interpreted with caution as being representative of a higher function nursing home 
populations. A final consideration is that even though evidence is suggestive that low 
muscle mass, muscle strength and gait speed are predictive of mortality, in the interest of 
a focused investigation we have only analyzed the influence of sarcopenia.19, 21 Future work 
should seek to overcome these limitations.  
Data from the present study will hold interest for those curious about the impact of 
long-term survival in nursing care. Not surprisingly, individuals continue to decline across 
markers of health and wellbeing, associated to unmet physical activity needs and escalating 
chronic disease.25, 26 However, while the prevalence of sarcopenia is high in this setting 
and increases with time in care, it appears that age is the strongest predictor of mortality. 
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In contrast, sarcopenia was associated with the consequence of and increased level of 
depression, but a relationship falls or hospitalization was not so apparent when compared 
to those with a non-sarcopenia diagnosis. Not unexpectedly, this study also demonstrated 
that with increased time in care individuals continue to decline across markers of health, 
but that change in SMI is more pronounced among non-sarcopenic residents. This work 
highlights the need for interventions into health and wellbeing in end-of life-care.  
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Table 1: Nursing home aged care cohort and gender demographic, physical and mental health 
data 18 months’ post-baseline assessment (N = 58).  
  Females (N = 41) Males (N=17) 
Age (y)       85.6 ± 8.2       87.2 ± 7.5       82.0 ± 8.9 
< 75 y (N) 8 3 5 
75 – 85 y (N)  12 8 6 
85 – 95 y (N) 33 21 4 
> 95 y (N) 5 9 2 
Length of Stay (days) 1970.1 ± 1403.7  2070.7 ± 1537.6  1729.9 ± 1010.9 
Height (cm)     159.5 ± 9.7      156.1 ± 8.1      167.9 ± 8.4 
Weight (kg)       68.5 ± 17.9        65.5 ± 16.6   75.7 ± 19.5 
BMI (kg/m2)       26.9 ± 6.2        26.8 ± 6.4 27.1 ± 6.1 
Fat mass (%)        36.0 ± 11.5  39.2 ± 10.7   29.8 ± 12.7 
SMI (kg/m2)         7.2 ± 1.8  6.9 ± 1.7  8.0 ± 1.9 
Lean mass (kg)       42.6 ± 9.0       40.1 ± 6.9  48.7 ± 10.6 
2.4-meter walk (m/s)           .2 ± .2 .3 ± .2  .1 ± .2 
Standing balance (s)  6.9 ± 10.2   8.0 ± 10.9  4.4 ± 7.9 
Chair standing (N)  5.2 ± 11.4   7.0 ± 12.9 1.3 ± 5.2 
SPPB summary score         2.5 ± 2.2  2.8 ± 2.4 1.6 ± 1.3 
Grip strength (kg)       12.7 ± 7.6        12.2 ± 7.1       14.2 ± 9.1 
Chronic diseases  7.8 ± 3.3  7.9 ± 3.4 7.4 ± 3.4 
< 5 (N) 6 4 2 
5 – 10 (N) 42 30 12 
> 10 (N) 10 7 3 
Fallen in Previous 6 mths (N)  24 16 8 
Bone Fracture in previous 2 y (N)  12 11 1 
MMSE       16.7 ± 9.3 17.2 ± 10.2        15.7 ± 7.2 
Severe (N) 16 9 7 
Moderate (N) 16 11 5 
Mild (N) 8 5 3 
Normal (N) 18 16 2 
GDS  4.6 ± 3.8  4.4 ± 4.0  5.2 ± 3.4 
Severe (N) 6 4 2 
Moderate (N) 6 5 1 
Mild (N) 16 6 10 
Normal (N) 30 26 4 
MNA  8.2 ± 3.1  8.3 ± 3.2  7.9 ± 2.9 
Malnourished (N) 20 14 6 
At Risk (N) 30 21 9 
Normal (N) 8 6 2 
Where appropriate data are expressed as mean ± standard deviation  
y = years, % = percent, kg = kilograms, m = metres, s = seconds, N = number, mths = months 
BMI = body mass index, SMI = skeletal muscle index, SPPB = Short physical performance battery, 
MMSE= Mini Mental State Examination, GDS= Geriatric Depression Scale, MNA= Mini Nutritional 
Assessment 
MMSE - normal (25-30), mild (21-24), moderate (14-20) or severe (< 13) impairment,  
GDS - normal (0-4), mild (5-8), moderate (9-11) or severe (12-15). 
MNA - malnourished (0-7), at risk of malnutrition (8-11) and normal (12 – 14) 
 
 
Table 2. Multivariate analyses for continuous variables from baseline diagnoses to follow up, controlled for age, gender, BMI, physical activity 
level and nutritional status. 
Variable Sarcopenia Non Sarcopenia p 
 Group Males Females Group Males Females  
Depression 6.5 ± 3.8 8.8 േ3. 1 5.1 േ 3.6 4.5 ± 3.5 4.7 േ 4.3 4.4 േ 3.3 .003 
N 36 14 22 60 16 44  
Cognitive change  -2.7 ± 7.0 -4.6 േ 8.0 -1.2 േ 6.1 -2.2 ± 6.8 -.8 േ 4.7 -2.6 േ 7.3 .940 
N 18 8 10 35 8 27  
Change SPPB .7 ± 1.2 .6 േ 1.0 .9 േ 1.3 1.3 ± 2.4 1.0 േ 1.8 1.3 േ 2.5 .690 
N 22 9 13 36 8 28  
Data are mean ± Standard Deviation, N = number of individual included, SPPB = Short Physical Performance Battery.  
Cognition is measured by the Mini Mental State Exam and Depression by the Geriatric Depression Scale. Data are in arbitrary units.  
Table 3. Association between Sarcopenia and death, falls and hospitalisation (18 Months Follow-up), unadjusted and after adjustment for various risk factors. Data 
are presented as risk ratios (95% Confidence Interval)  
 Death 
Unadjusted 1.03 (0.49 – 2.19) 
Fall 
Unadjusted 1.02 (0.53 – 1.97) 
Hospitalization 
Unadjusted 1.25 (0.73 – 2.14) 
Model 2 Model 3 Model 2 Model 3 Model 2 Model 3 
Sarcopenia 0.85 (0.39 – 1.86) 0.81 (0.33 – 1.98) 0.98 (0.39 – 1.86) 0.74 (0.34 – 1.63) 1.27 (0.74 – 2.19) 1.27 (0.73 – 2.22) 
Age 1.06 (0.99 – 1.13) 1.06 (1.00 – 1.13) 1.03 (0.97 – 1.08) 1.04 (0.99 – 1.01) 0.96 (0.96 – 1.03) 1.00 (0.97 – 1.03) 
Gender (Female) 0.54 (0.24 – 1.11) 0.50 (0.23 – 1.09) 1.37 (0.60 – 3.14) 1.34 (0.59 – 3.03) 0.99 (0.56 – 1.78) 0.95 (0.54 – 1.66) 
Physical Activity (Active)
 
1.37 (0.61 – 3.01) 
 
0.58 (0.17 – 1.11) 
 
0.64 (0.36 – 1.13) 
Nutritional Status (Normal)
 
0.73 (0.29 – 1.87) 
 
0.43 (0.29 – 1.15) 
 
0.91 (0.49 – 1.70) 
Body Mass Index
 
0.98 (0.90 – 1.07) 
 
0.99 (0.93 – 1.06) 
 
1.03 (0.98 – 1.07) 
Model 1 for each variable is the unadjusted model. Model 2: adjusted for age and gender; Model 3: adjusted for age, gender, physical activity, nutritional status and body mass index. 
 
1 
 
Table 4. Eighteen-month follow-up of residential aged care adults diagnosed with or without sarcopenia at baseline (N = 58)  
 Sarcopenic Non sarcopenic F p* 
Baseline Follow-up Baseline Follow-up 
Fat mass (%) 33.8 ± 13.9 32.9 ± 12.3 38.1 ± 10.6 37.9 ± 10.7 .061 .805 
Body mass index (kg/m2) †         23.9 ± 5.9        24.1 ± 6.2        29.9 ± 5.2        28.6 ± 5.7 1.228 .272 
SMI (kg/m2)† 5.9 ± 1.5          6.1 ± 1.2          8.7 ± 1.9 7.8 ± 1.8 4.389 .041 
Lean mass (kg)‡        39.9 ± 9.2  37.9 ± 11.7 46.0 ± 11.5        44.4 ± 8.9 .023 .881 
Walking speed (m/s)            .3 ± .2  .2 ± .2 .4 ± .2 .2 ± .2 1.721 .195 
Standing balance (s)        11.8 ± 9.5    6.6 ± 10.0 14.4 ± 10.5  7.1 ± 10.4 .859 .358 
Chair standing (s)        22.8 ± 5.4  10.1 ± 16.7        20.3 ± 6.1 11.1 ± 12.8 .156 .699 
SPPB summary          3.0 ± 2.2  2.2 ± 2.0 3.8 ± 2.8 2.5 ± 2.3 .945 .355 
Grip strength (kg) ‡        14.4 ± 7.0  9.8 ± 6.6        17.9 ± 7.5        14.6 ± 7.7 973 .328 
Falls in previous 6 months (n)            .5 ± 1.0  1.0 ± 1.7 .3 ± .7   .9 ± 1.6 .000 .986 
Hospital admission in previous year (n) 1.8 ± 1.1  1.5 ± 1.7 1.6 ± 1.4 1.9 ± 2.4 .736 .404 
MMSE         18.6 ± 6.8        15.8 ± 8.1        21.0 ± 6.1        18.9 ± 8.9 .077 .782 
GDS  5.4 ± 3.6 4.9 ± 2.7 4.3 ± 3.3 3.7 ± 3.4 .022 .883 
MNA  9.4 ± 3.1 7.9 ± 3.4        10.9 ± 2.2 8.6 ± 2.5 .755 .389 
Data are expressed as mean ± standard deviation.  
* groups x time ANOVA 
Between group ANOVA: †< .001; ‡ <.05. 
% = percent, kg = kilograms, m = metres, s = seconds 
SMI = skeletal muscle index, SPPB = Short physical performance battery, MMSE= Mini Mental State Examination, GDS= Geriatric Depression Scale, MNA= Mini 
Nutritional Assessment 
 
